Justine Herndon

Justine Herndon

Auto-generated profile, based on publicly available information

Justine Herndon

Division of Endocrinology, Diabetes, and Metabolism, Mayo Clinic , Rochester, MN 55905

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Endocrine Practice
Verified
Journal Article
Closed access
JHJustine S. Herndon
Justine S. Herndon
AMArvind K. Maheshwari
Arvind K. Maheshwari
TNTodd B. Nippoldt
Todd B. Nippoldt
SCSara J. Carlson
Sara J. Carlson
CDCaroline J. Davidge-Pitts
Caroline J. Davidge-Pitts
ACAlice Y. Chang
Alice Y. Chang

24 November 2023 in Clinical Endocrinology
Verified
Journal Article
Closed access
JSJasmine Saini
Jasmine Saini
RGRaul Gregg Garcia
Raul Gregg Garcia
JHJustine Herndon
Justine Herndon
DEDana Erickson
Dana Erickson
LGLucinda Gruber
Lucinda Gruber
IBIrina Bancos
Irina Bancos

17 April 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
JHJustine Herndon
Justine Herndon
NGNidhi Gupta
Nidhi Gupta
CDCaroline Davidge-Pitts
Caroline Davidge-Pitts
NINicole Imhof
Nicole Imhof
CGCesar Gonzalez
Cesar Gonzalez
ACAlice Y Chang
Alice Y Chang
Context Transgender and gender diverse (TGD) individuals have greater access to genital surgery (GS) with improved insurance coverage and access to trained surgeons and interdisciplinary gender-affirming providers. Objective To determine perioperative medical and behavioral health outcomes in transfeminine (TF) individuals undergoing GS, with use of a specific gender-affirming hormone therapy (GAHT) algorithm based on individualized risk factor assessment. Methods In this retrospective observational cohort study, we collected preoperative and postoperative data from 183 TF individuals at a single tertiary referral center from 2017 to 2022, grouping patients by those who continued estradiol (Group 1) vs those who had temporarily discontinued estradiol for 2 to 6 weeks preoperatively (Group 2). Data included clinical and biochemical assessment, GAHT regimens, validated behavioral health measures, and postoperative complications. Main outcomes included venous thromboembolism (VTE) incidence, non-VTE postoperative complication incidence, and change in behavioral health assessments. Results The majority of individuals continued estradiol perioperatively (Group 1; 138 [75.4%]). Individuals who temporarily held estradiol preoperatively (Group 2; 45 [24.6%]) were statistically older (P < .01), had higher incidence of cardiometabolic comorbidities (P < .01), and higher Caprini scores (P < .01). Group 1 was statistically more likely to use oral estradiol (P < .01). One episode (0.05%) of VTE occurred (Group 1). There was no significant difference in postoperative complications or behavioral health measures between groups. Conclusion An individualized algorithm for preoperative hormone management for TF GS resulted in perioperative continuation of GAHT for the majority of individuals without significantly increasing the risk for postoperative surgical complications, while maintaining stable behavioral health measures perioperatively.

2 December 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
JHJustine Herndon
Justine Herndon
RKRavinder Jeet Kaur
Ravinder Jeet Kaur
MRMark Romportl
Mark Romportl
ESEmily Smith
Emily Smith
AKAmy Koenigs
Amy Koenigs
IBIrina Bancos
Irina Bancos
Context Hyperglycemia is a common complication of Cushing syndrome (CS). Objective We aimed to determine the impact of curative procedure on hyperglycemia and its management in patients with CS. Methods This retrospective longitudinal cohort study took place 2000 to 2019 in a referral center among adults with endogenous CS and hyperglycemia. Main outcome measures included glycated hemoglobin A1c (HbA1c), intensity of hyperglycemia therapy, and improvement of hyperglycemia. Results In 174 patients with CS (pituitary in 106, ectopic in 25, adrenal in 43), baseline median HbA1c was 6.9% (range, 4.9-13.1), with 41 (24%) patients not on any therapy for hyperglycemia, 93 (52%) on oral medications, and 64 (37%) on insulin (median daily units of 58; range, 10-360). Following CS remission, at the end of follow-up (median 10.5 months), 37 (21%) patients demonstrated resolution of hyperglycemia, 82 (47%) demonstrated improvement, and 55 (32%) had no change or worsening in hyperglycemia. At the end of follow-up, HbA1c decreased by 0.84% (P < .001) and daily insulin dose decreased by a mean of 30 units (P < .001). Biochemical hypercortisolism severity score (severe vs moderate/mild: odds ratio [OR] of 2.4 [95% CI, 1.1-4.9]), and CS subtype (nonadrenal vs adrenal: OR of 2.9 [95% CI, 1.3-6.4]), but not type of hyperglycemia (diabetes vs prediabetes: OR of 2.1 [0.9-4.9]) were associated with hyperglycemia improvement at the end of follow-up. Conclusion Two-thirds of patients with CS and hyperglycemia demonstrate resolution or improvement of hyperglycemia after a curative procedure. Close monitoring during CS recovery is needed to ensure appropriate therapy modification.

16 March 2023 in Clinical Endocrinology
Verified
Journal Article
Closed access
JHJustine Herndon
Justine Herndon
CHChristopher Hallemeier
Christopher Hallemeier
Krishan R. JethwaKrishan R. Jethwa
Krishan R. Jethwa
ASAfreen Shariff
Afreen Shariff
IBIrina Bancos
Irina Bancos

28 January 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
JHJustine Herndon
Justine Herndon
JMJohn Anderson McNeil
John Anderson McNeil
SWSalym Winter
Salym Winter
ACAlice Y Chang
Alice Y Chang
Background: Polycystic ovary syndrome (PCOS) affects 10% to 13% of individuals assigned female at birth (AFAB), although a greater prevalence is reported in transgender/gender diverse individuals (TGD) (23.8-38.8%). Testosterone therapy (TT) in TGD individuals is linked to worsening cardiovascular risk factors (CVRFs). Whether TT induces more adverse cardiometabolic changes in TGD with PCOS than TGD without PCOS remains uncertain. Objective: To compare the effects of TT on CVRF in TGD with and without PCOS. Methods: We retrospectively reviewed 373 records to identify 62 TGD with PCOS (withestablished guideline criteria) and 132 age-matched TGD without PCOS. Data included longitudinal anthropometric measurements, hormone and metabolic parameters, and CVRF before and after TT. Group comparison of PCOS vs without PCOS before and after TT was conducted via independent t-tests, Mann–Whitney-U, and Chi-square. Results: At baseline, TGD with PCOS had significantly greater body mass index (BMI), obesity prevalence, and, after controlling for BMI, baseline metformin use. There were no significant differences between TGD with and without PCOS when comparing intra-participant changes after TT. Controlling for BMI, TGD with PCOS on TT exhibited significantly greater hyperlipidemia prevalence, alanine transaminase (ALT) levels, and bioavailable testosterone concentrations than TGD without PCOS on TT. Conclusion: Greater baseline cardiometabolic risk was largely BMI-related in TGD with PCOS compared to TGD without PCOS. Only hyperlipidemia and elevated ALT were more prevalent during TT after adjusting for BMI. These findings support cardiometabolic monitoring during TT in all TGD individuals without significant increased risk with PCOS history.